ABILIFY GAINS EXPANDED BIPOLAR AND SCHIZOPHRENIA INDICATIONS
The FDA has approved Abilify (aripiprazole, from Bristol-Myers Squibb and Otsuka) for the maintenance treatment of manic and mixed episodes associated with bipolar I disorder, with or without psychotic features, in children 10-17 years of age and for the maintenance treatment of schizophrenia in adolescents 13-17 years of age.
Date Posted: May 9, 2008

FDA APPROVES STRATTERA FOR ADHD MAINTENANCE
The FDA has approved Strattera (atomoxetine HCl capsules, from Eli Lilly) for maintenance treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children ≥6 years of age.
Date Posted: May 8, 2008

GENERIC DOVONEX SCALP SOLUTION LAUNCHED
Fougera has received FDA approval to market the generic version of Warner-Chilcott’s Dovonex Scalp Solution (calcipotriene topical solution).
Date Posted: May 6, 2008

KING DISCONTINUES TILADE INHALER
King Pharmaceuticals has decided to discontinue the manufacturing of Tilade Inhaler (nedocromil sodium inhalation aerosol).
Date Posted: May 5, 2008

More drug news...